AU2020358156B2 - Method for treating HIV with cabotegravir and rilpivirine - Google Patents

Method for treating HIV with cabotegravir and rilpivirine Download PDF

Info

Publication number
AU2020358156B2
AU2020358156B2 AU2020358156A AU2020358156A AU2020358156B2 AU 2020358156 B2 AU2020358156 B2 AU 2020358156B2 AU 2020358156 A AU2020358156 A AU 2020358156A AU 2020358156 A AU2020358156 A AU 2020358156A AU 2020358156 B2 AU2020358156 B2 AU 2020358156B2
Authority
AU
Australia
Prior art keywords
salt
rilpivirine
cabotegravir
intramuscular
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020358156A
Other languages
English (en)
Other versions
AU2020358156A1 (en
Inventor
Herta Maria Ludovica CRAUWELS
Susan L. FORD
David Andrew MARGOLIS
Stefaan Louis F. ROSSENU
William Robert SPREEN
Rodica Mihaela VAN SOLINGEN-RISTEA
Peter Evan Owen WILLIAMS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Sciences Ireland ULC
ViiV Healthcare Co
Original Assignee
Janssen Sciences Ireland ULC
ViiV Healthcare Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland ULC, ViiV Healthcare Co filed Critical Janssen Sciences Ireland ULC
Publication of AU2020358156A1 publication Critical patent/AU2020358156A1/en
Application granted granted Critical
Publication of AU2020358156B2 publication Critical patent/AU2020358156B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020358156A 2019-10-01 2020-10-01 Method for treating HIV with cabotegravir and rilpivirine Active AU2020358156B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962908995P 2019-10-01 2019-10-01
US201962908882P 2019-10-01 2019-10-01
US62/908,882 2019-10-01
US62/908,995 2019-10-01
US202063037782P 2020-06-11 2020-06-11
US63/037,782 2020-06-11
US202063052214P 2020-07-15 2020-07-15
US63/052,214 2020-07-15
PCT/IB2020/059185 WO2021064618A1 (en) 2019-10-01 2020-10-01 Method for treating hiv with cabotegravir and rilpivirine

Publications (2)

Publication Number Publication Date
AU2020358156A1 AU2020358156A1 (en) 2022-04-21
AU2020358156B2 true AU2020358156B2 (en) 2024-06-06

Family

ID=72826936

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020358156A Active AU2020358156B2 (en) 2019-10-01 2020-10-01 Method for treating HIV with cabotegravir and rilpivirine

Country Status (11)

Country Link
US (3) US20220347174A1 (enExample)
EP (1) EP4037661A1 (enExample)
JP (1) JP7791083B2 (enExample)
KR (1) KR20220074880A (enExample)
CN (2) CN114502166A (enExample)
AU (1) AU2020358156B2 (enExample)
CA (1) CA3155587A1 (enExample)
CL (1) CL2022000790A1 (enExample)
IL (1) IL290716A (enExample)
MX (1) MX2022003945A (enExample)
WO (1) WO2021064618A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3103522C (en) 2018-07-16 2023-11-21 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
WO2023222755A1 (en) * 2022-05-17 2023-11-23 Janssen Sciences Ireland Unlimited Company Treatment or prevention of hiv infection
TW202408526A (zh) * 2022-05-17 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 治療或預防hiv感染(一)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016732A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6319946B1 (en) 1999-02-12 2001-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of aspartyl protease
PT3366278T (pt) 2006-06-23 2024-10-21 Janssen Sciences Ireland Unlimited Co Suspensões aquosas de tmc278
KR101811314B1 (ko) * 2009-09-22 2017-12-26 얀센 알 앤드 디 아일랜드 Ｈｉｖ 감염의 치료 및 예방
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
CN104902905A (zh) 2012-12-14 2015-09-09 葛兰素史克有限责任公司 药物组合物
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EA201790495A1 (ru) 2014-09-26 2017-09-29 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Фармацевтические композиции длительного действия
CN109568328A (zh) * 2017-09-29 2019-04-05 重庆药友制药有限责任公司 一种用于预防和治疗hiv感染的药物组合物
EP3986561B1 (en) * 2019-06-19 2024-02-14 VIIV Healthcare UK (No.5) Limited Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019016732A1 (en) * 2017-07-21 2019-01-24 Viiv Healthcare Company REGIMES FOR THE TREATMENT OF HIV AND AIDS INFECTIONS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C ORKIN et al., "Long-active cabotegravir + rilpivirine for HIV maintenance: FLAIR week-48 results ", HIV MEDICINE (April 2019), vol. 20, suppl. 5, pages 3 - 15, abstr. no. 10. DOI: https://onlinelibrary.wiley.com/doi/full/10.1111/hiv.12738 *
CHLOE ORKIN et al. "LONG-ACTING CABOTEGRAVIR + RILPIVIRINE FOR HIV MAINTENANCE: FLAIR WEEK 48 RESULTS", 25TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION, BHIVA 2019, 7 March 2019, URL: https://www.natap.org/2019/CROI/croi_65.htm *
MARGOLIS D A et al., THE LANCET, 2017, vol. 390, no. 10101, pages 1499 - 1510, DOI: 10.1016/S0140-6736(17)31917-7 *

Also Published As

Publication number Publication date
JP7791083B2 (ja) 2025-12-23
CL2022000790A1 (es) 2022-11-25
IL290716A (en) 2022-04-01
EP4037661A1 (en) 2022-08-10
CN118416069A (zh) 2024-08-02
WO2021064618A1 (en) 2021-04-08
JP2022550828A (ja) 2022-12-05
US12636285B2 (en) 2026-05-26
US12636286B2 (en) 2026-05-26
CN114502166A (zh) 2022-05-13
US20220347174A1 (en) 2022-11-03
CA3155587A1 (en) 2021-04-08
AU2020358156A1 (en) 2022-04-21
US20250302829A1 (en) 2025-10-02
US20250302830A1 (en) 2025-10-02
MX2022003945A (es) 2022-04-25
KR20220074880A (ko) 2022-06-03

Similar Documents

Publication Publication Date Title
US20250302830A1 (en) Method for treating hiv with cabotegravir and rilpivirine
AU2020293739B2 (en) Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
JP2025066802A (ja) ウィルソン病を治療するためのビスコリンテトラチオモリブデート
TWI879737B (zh) 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法
Yu et al. Pharmacokinetic drug-drug interactions involving antiretroviral agents: an update
AU2018304591A1 (en) Regimens for treating hiv infections and aids
AU2024318637A1 (en) Obefazimod for treatment of ulcerative colitis
Dirajlal-Fargo et al. Pediatric antiretroviral therapy
WO2026050513A1 (en) Tolebrutinib for multiple sclerosis
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Pakyz et al. Overview of protease inhibitors
US20210290590A1 (en) Methods of treating subjects infected with hiv
Koren et al. Scientific basis of antiretroviral therapy
US20220096487A1 (en) Methods for treating hiv with dolutegravir and lamivudine
Dihydrochloride AHFS® firstRelease™
Pandit et al. PRINCIPLES AND SCIENTIFIC BASIS OF HIV THERAPY
Tablets et al. Antiretroviral Agent
WO2014193589A1 (en) Cancer treatment method
Venter et al. Stavudine
Blonk et al. and David M. Burger
Injection Full prescribing information
ULC et al. Pr Mylan-Efavirenz
Merai et al. New Approaches to Antiretroviral Therapy-Raltigravir
Harsh New drugs
Flamm Highlights in the Treatment of Hepatitis C Virus From the 2016 AASLD Liver Meeting

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)